University Clinic of Pediatrics, Faculty of Medicine of the University of Coimbra, Coimbra, Portugal.
Medical Pediatrics Unit, Hospital Pediátrico, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal.
Eur J Pediatr. 2022 Jul;181(7):2809-2819. doi: 10.1007/s00431-022-04477-w. Epub 2022 May 6.
Trisomy 18 is an autosomal chromosomal disorder characterized by the presence of an extra 18 chromosome. In the last decades, and as novel therapeutic options emerged, a paradigm shift on the treatments available to these children occurred, establishing the need to deepen the knowledge regarding the management/treatment of children diagnosed with trisomy 18. This retrospective cohort study sought to characterize the clinical path and survival of the children with the diagnosis of trisomy 18 followed in a tertiary pediatric hospital between 1995 and 2020. Medical records were reviewed, and epidemiological and clinical features and follow-up data were collected. Six patients were identified, two with mosaicism (33.3%) and four were female (66.7%). All had cardiovascular, cognitive, and physical development anomalies or minor congenital anomalies. Most presented neurological anomalies (n = 4, 66.7%) and feeding difficulties (n = 4, 66.7%). Four children (66.7%) required medical devices or equipment and all required chronic medication. Two children (33.3%) underwent surgical interventions. Four children (66.7%) were hospitalized in the last year of life. Three patients had a do not resuscitate order (50%) but only one child was referred to a pediatric palliative care team (16.7%). One-month, 1-year, and 10-year survival were 66.7% (n = 4), 33.3% (n = 2, both with mosaicism), and 16.7% (n = 1, with mosaicism) respectively.
Knowledge of the multiple comorbidities and complex care needs of children with this syndrome is crucial. Every-day care and decisions about invasive treatments may raise ethical issues. Early referral to pediatric palliative care teams is essential to promote a holistic advanced care plan for both the patient and his family.
• The increase in survival and the high morbimortality that trisomy 18 still entails demands a careful deliberation on the use of invasive treatment.
• Recent studies show that the labels of "incompatible with life"/"lethal" are not adequate, establishing a need to change this mindset. • The development of pediatric palliative care teams in the last decade and early referral allow for an optimal individualized advanced care plan. Under-referral to pediatric palliative care teams persists and efforts must be made to increase awareness of their existence and role in patient care.
18 三体是一种常染色体染色体疾病,其特征是存在额外的 18 号染色体。在过去的几十年中,随着新的治疗选择的出现,这些儿童的治疗方法发生了范式转变,需要加深对诊断为 18 三体的儿童的管理/治疗的认识。这项回顾性队列研究旨在描述 1995 年至 2020 年间在一家三级儿科医院接受诊断的 18 三体患儿的临床路径和生存情况。回顾了病历,并收集了流行病学和临床特征及随访数据。确定了 6 名患者,其中 2 名存在嵌合体(33.3%),4 名是女性(66.7%)。所有患者均有心血管、认知和身体发育异常或轻微先天性异常。大多数患者存在神经系统异常(n=4,66.7%)和喂养困难(n=4,66.7%)。4 名儿童(66.7%)需要医疗设备或仪器,所有儿童均需要长期药物治疗。2 名儿童(33.3%)接受了手术干预。4 名儿童(66.7%)在生命的最后一年住院。3 名患儿有不复苏医嘱(50%),但只有 1 名患儿被转介至儿科姑息治疗团队(16.7%)。1 个月、1 年和 10 年生存率分别为 66.7%(n=4)、33.3%(n=2,均为嵌合体)和 16.7%(n=1,为嵌合体)。
了解患有这种综合征的儿童的多种合并症和复杂的护理需求至关重要。日常护理和对侵入性治疗的决策可能会引发伦理问题。尽早转介至儿科姑息治疗团队对于为患者及其家属制定整体先进的护理计划至关重要。
• 18 三体的存活率提高和高病死率仍然需要仔细考虑侵入性治疗的使用。
• 最近的研究表明,“无法生存”/“致命”的标签并不合适,因此需要改变这种思维方式。• 儿科姑息治疗团队在过去十年中的发展和早期转介允许制定最佳的个体化先进护理计划。儿科姑息治疗团队的转介仍然不足,必须努力提高人们对其存在及其在患者护理中的作用的认识。